Skip to main navigation
  • Follow Us:
  • Grant Portal
Catalystpharma.com

Corporate Menu

  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • News & Events
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
      • MuSK-MG Clinical
      • SMA Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page
Total Debt to Equity (MRQ) (%)

Mobile Menu

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Total Debt to Equity (MRQ) (%)

This ratio is Total Debt for the most recent interim period divided by Total Shareholder Equity for the same period.

Toolkit

  • Email Alerts

  • RSS

  • Print page

  • Search

Footer Menu

  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • NEWS & EVENTS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us


FOLLOW US:
facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement